How does ALK rearrangement affect Ovarian Cancer treatment
ALK Rearrangement and Ovarian Cancer Treatment
I appreciate your question about ALK rearrangement in ovarian cancer. Let me provide you with what the current evidence shows, along with important context about this finding.
What ALK Rearrangement Is
ALK (anaplastic lymphoma kinase) is a gene that, when rearranged or mutated, can drive cancer cell growth. An ALK rearrangement means the ALK gene has been altered in a way that may make cancer cells dependent on this abnormal protein for survival.
Current Evidence in Ovarian Cancer
Based on the NCCN Guidelines for Ovarian Cancer (Version 3.2025), the guidelines recommend comprehensive tumor molecular testing to identify potential benefit from targeted therapeutics. The recommended testing includes:
- BRCA1/2 status
- HRD (homologous recombination deficiency) status
- HER2 status
- MSI (microsatellite instability)
- MMR (mismatch repair)
- TMB (tumor mutational burden)
- BRAF, FRα (FOLR1), RET, and NTRK if prior testing did not include these markers
Important note: While ALK rearrangements are recognized in some cancer types (particularly lung cancer and certain lymphomas), ALK is not specifically listed in the NCCN ovarian cancer molecular testing recommendations as a standard marker that typically affects treatment decisions in ovarian cancer.
What This Means for You
If your testing has identified an ALK rearrangement:
- This is relatively uncommon in ovarian cancer - ALK rearrangements are much more frequently seen in lung cancer and other malignancies
- Your specific case requires expert evaluation - Because this is not a standard ovarian cancer finding, your oncologist should:
- Confirm the testing methodology and results
- Determine if this represents a true ALK-driven process
- Evaluate whether ALK-targeted therapies (like ALK inhibitors) might be appropriate
Questions to Ask Your Oncology Team
- Can you explain what the ALK rearrangement means in the context of my specific ovarian cancer?
- How confident is the laboratory in this finding, and was it confirmed with additional testing methods?
- Are there ALK-targeted therapies that might be considered for my case, and would I be a candidate?
- Should I pursue additional molecular testing to identify other potential treatment targets?
- Are there clinical trials available for patients with ALK-rearranged ovarian cancer?
The Broader Picture
According to NCCN Guidelines, ovarian cancer treatment decisions are primarily guided by:
- BRCA mutation status (for PARP inhibitor eligibility)
- HRD status (homologous recombination deficiency)
- Platinum sensitivity (how the cancer responds to platinum-based chemotherapy)
- Histologic type and grade
Your oncologist will integrate the ALK finding into this complete clinical picture to determine the most appropriate treatment approach for YOUR specific situation.
Next Steps
I'd recommend:
- Request a detailed explanation of the ALK testing results and what they mean for ovarian cancer specifically
- Ask about molecular tumor boards - many cancer centers have multidisciplinary teams that review unusual molecular findings
- Explore clinical trials - given the rarity of ALK rearrangement in ovarian cancer, clinical trials may offer innovative treatment options
- Consider a second opinion from a gynecologic oncologist at an NCCN Member Institution if you want additional expertise
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Grounded in NCCN Guidelines for Patients: Ovarian Cancer — the same guidelines oncologists use.
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated May 17, 2026. Informational only — not a substitute for your oncology team.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Source Guidelines
NCCN Guidelines for Patients: Ovarian Cancer (2026)Browse all NCCN Guidelines for Patients →Related Services
Services that may help with treatment for Ovarian Cancer patients
Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about Ovarian Cancer
- How does NTRK fusion affect Ovarian Cancer treatment options
- How does chemotherapy for Ovarian Cancer affect my immune system
- What should caregivers know about Ovarian Cancer treatment
- What happens if I choose no treatment for Ovarian Cancer
- What is the risk of getting a second cancer after Ovarian Cancer treatment
- Can I get vaccinated during Ovarian Cancer treatment
- Does Medicaid cover Ovarian Cancer treatment
- Are there any herbs that interact with Ovarian Cancer treatment